D. Bowman

发表

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

C. Redmond, J. Costantino, D. Wickerham, 1989, The New England journal of medicine.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

B Fisher, J Costantino, C. Redmond, 1996, Journal of the National Cancer Institute.

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.

C. Redmond, R. Foster, D. Wickerham, 1989, The New England journal of medicine.

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and

C. Redmond, J. Costantino, D. Wickerham, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy of bone scanning in the follow-up of patients with operable breast cancer

R. Foster, A. Glass, B. Fisher, 2005, Breast Cancer Research and Treatment.

A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.

D. Tu, D. Walde, M. Blackstein, 2007, Annals of Oncology.

Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials.

C. Redmond, D. Wickerham, N. Wolmark, 1989, Annals of internal medicine.

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.

B Fisher, C. Redmond, D. Wickerham, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

Anna L. Brown, C. Redmond, D. Wickerham, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy

H. Rockette, C. Redmond, D. Wickerham, 2005, Breast Cancer Research and Treatment.

The management of disseminated testicular cancer.

D. Bowman, B. Weinerman, E. Ramsey, 1979, British journal of urology.

Clinical practice guidelines for the care and treatment of breast cancer : 8 . Adjuvant systemic therapy for women with node-positive breast cancer ( 2001 update )

C. Sawka, D. Bowman, Carol Sawka, 2022 .

Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.

C. Redmond, D. Wickerham, N. Wolmark, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.

C. Redmond, N. Wolmark, B. Fisher, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential methotrexate and 5-FU in the treatment of colorectal cancer.

M. Levitt, D. Bowman, B. Schacter, 1982, Cancer treatment reports.

Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.

E. Eisenhauer, J. Ragaz, K. Pritchard, 1984, Cancer treatment reports.

Treatment of primary breast cancer with chemotherapy and tamoxifen.

C. Redmond, N. Wolmark, B. Fisher, 1981, The New England journal of medicine.

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

D. Tu, V. Bramwell, B. Norris, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term tamoxifen citrate use and potential ocular toxicity.

C. Redmond, J. Costantino, N. Wolmark, 1998, American journal of ophthalmology.

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group.

N. Boyd, J. Ragaz, M. Knowling, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Physiologic Observations in a Controlled Clinical Trial of the Antiemetic Effectiveness of 5, 10, and 15 mg of Δ9‐Tetrahydrocannabinol in Cancer Chemotherapy. Ophthalmologic Implications

D. Bowman, B. Weinerman, M. Levitt, 1981, Journal of clinical pharmacology.

Hypercalcemia in small cell (oat cell) carcinoma of the lung. Coincident parathyroid adenoma in one case

M. Levitt, D. Bowman, W. J. Dubé, 1975, Cancer.

IgD kappa plasma cell dyscrasias: extraosseous manifestations including isolated leptomeningitis.

J. Johnston, D. Bowman, N. Pettigrew, 1982, American Journal of Clinical Pathology.

Primary carcinoid of the testis with metastases.

D. Bowman, E. Ramsey, D. Hosking, 1981, The Journal of urology.

Information needs and decisional preferences in women with breast cancer.

K C Carriere, J A Sloan, K. Carriere, 1997, JAMA.

Clinical practice guidelines for the care and treatment of breast cancer: 7. Adjuvant systemic therapy for women with node-negative breast cancer (2001 update)

C. Sawka, D. Bowman, 2022 .